Home Blog Page 275

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

By
Advertorial Desk
-
  • Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages
  • Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million
  • The collaboration further expands the parties’ 2025 oncology biosimilars partnership

SHANGHAI, Aug. 17, 2026 /PRNewswire/ — On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.

In April 2025, the two companies entered into an exclusive commercialization partnership for HLX13, Henlius’ proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. This new agreement further deepens the existing oncology biosimilars collaboration between the two parties.

Under the strategic collaboration agreement, Henlius will grant Sandoz exclusive rights for registration and commercialization outside China for up to 10 partnered products worldwide. Most of the partnered products are currently at early stages of development, and the two parties will collaborate closely from the early stages of project development. Based on a multi-product portfolio framework, the collaboration will cover key stages across the product lifecycle, including product development, regulatory submissions, manufacturing, launch, commercialization and lifecycle management.

Henlius will leverage its integrated biologics platform to undertake the development, manufacturing and supply of the partnered products, thereby accelerating the development and translation of early-stage molecules. Sandoz has a diversified portfolio of approximately 1,300 medicines, a business presence in around 100 countries and reaches over 1 billion patients worldwide. It has established a strong track record in product registration, market access, launch and commercialization. Leveraging its extensive global footprint, deep localized operating capabilities and market-validated commercialization system, Sandoz will incorporate ex-China market insights and commercial perspectives into product development and registration strategies at an early stage, driving the efficient execution of the partnered products in global markets. Through deep synergies across the entire product lifecycle, the two parties will continue to unlock the global commercial value of the partnered products.

The initial assets covered under the agreement include HLX05-N, a proposed cetuximab biosimilar; HLX16, a proposed evolocumab biosimilar; and a proposed belimumab biosimilar. In addition, Sandoz has obtained an option for HLXTE-HAase1001, a recombinant human hyaluronidase. Based on these arrangements, Sandoz will pay Henlius an upfront payment, relevant milestone payments and a non-refundable option fee totaling up to US$322 million. In 2026, the total invoiced amount expected for Henlius is up to US$100.5 million.

For HLX05-N, the exclusive collaboration territory covers the United States, Canada, the European Union and certain other European countries including the United Kingdom and Switzerland, Japan, Australia and New Zealand, while semi-exclusive rights apply in certain countries and regions in Asia, as well as other markets. For HLX16 and the proposed belimumab biosimilar, the exclusive collaboration territory covers all markets worldwide outside China.

This collaboration represents an important part of Henlius’ globalization strategy. It not only demonstrates the company’s comprehensive strengths in biologics R&D, quality systems, international registration, large-scale manufacturing and global supply, but also further validates the global value of its biosimilars platform. Henlius has established a diversified pipeline spanning biosimilars and innovative biologics, with multiple self-developed biologic products approved in China, the EU, the United States and other global markets.

By partnering with leading global pharmaceutical companies, Henlius continues to expand product access to more countries and regions and accelerate the global commercialization of more biologics. At the same time, the company is continuing to build its own ex-China commercialization capabilities and, based on the market potential, competitive landscape and commercialization needs of different products, is flexibly adopting a combination of independent advancement and strategic partnerships to bring products to global markets through diversified pathways and further unlock the value of its R&D, manufacturing and global supply platforms.

About HLX05-N

HLX05-N is a cetuximab injection biosimilar independently developed by Henlius, intended for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma. In July 2026, the first patient has been dosed in a phase 1 clinical study of cetuximab injection biosimilar HLX05-N independently developed by Henlius in patients with metastatic colorectal cancer (mCRC) in China. According to the statistics released by IQVIA MIDAS™ (IQVIA is a global provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), the sales revenues of cetuximab injection globally amounted to approximately USD1.696 billion in 2025.

About HLX16

HLX16 is an evolocumab biosimilar independently developed by Henlius, intended for the treatment of primary hypercholesterolemia (including heterozygous familial and non-familial types). Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™, the sales revenues of evolocumab injection globally amounted to approximately USD6.602 billion in 2025.

About the proposed belimumab biosimilar

Belimumab biosimilar, independently developed by Henlius, is intended for the treatment of systemic lupus erythematosus and lupus nephritis. Currently, this product is in the preclinical research stage. According to the statistics released by IQVIA MIDAS™, the sales revenues of belimumab injection globally amounted to approximately USD2.475 billion in 2025.

About HLXTE-HAase1001

HLXTE-HAase1001 is a recombinant human hyaluronidase independently developed by Henlius, intended to transform time-consuming intravenous infusion into rapid subcutaneous injection, thereby significantly shortening administration time and improving patient experience. Currently, this product is in the process development stage.

About Henlius

Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. Up to date, Henlius has achieved regulatory approvals for 10 products across over 60 countries and regions worldwide, including eight approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and five products approved by the European Commission (EC), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.

Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and for perioperative gastric cancer. Up to date, it has been approved in 50 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb dulpatatug (HLX22) — are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.

To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.

Strategic Investment in Production Expansion: Impact Fusion International (IFUS) Installs Proprietary Machinery to Enhance Production Capacity

By
Advertorial Desk
-
Napoleonville, Louisiana – Newsfile Corp. – August 17, 2026 – IFUS (OTCID: IFUS) has installed a retrofitted Selco/Mosley Badger Double Ram Press. Per the Equipment Commissioning Plan, both SGP+™ and SAG™ will now be produced for validation to ensure consistent and sustainable product quality.

Delivery and installation, supported by the Harris Bailer Distributor Crigler, has ensured that retrofitted production capability is consistent with IFUS’ Proprietary Formulation and Production Requirements. The implementation of the detailed Project Commissioning Plan has enabled another significant step in IFUS’s Growth Strategy so as to meet growing market demand for both SGP+™, SupremeAG™, and SupremeOR™. This Growth Strategy is being accomplished through enhanced production efficiency, further definition of our processing Footprint, and improved costs / revenue / profit structures.

Following a thorough evaluation of IFUS’ market position, as reflected by increasing customer demand and back orders, the Company approved a significant strategic investment in to expanding production capacity and efficiency. The investment enables IFUS to increase through put, while lowering production costs.

The rated through put of the newly installed proprietary and Selco/Mosley Badger Double Ram Press machine, allows IFUS to address concerns from customers wanting larger orders fulfilled daily. Large cattle and dairy operations can easily require 300-bales/day (or more). The new machinery will enable IFUS to initially produce 600-bales per day (while using only 25% of the new machine’s rated hourly throughput). At present, both SGP+™ and SupremeAG™ are priced so as to easily justify this OPEX/CAPEX investment.

The newly acquired and retrofitted machinery is significantly more advanced than the previous machine, as it has both analog and digital capabilities, enabling operations to remotely troubleshoot with the manufacturer anywhere there is internet access (should it be required). These features can dramatically reduce down-time, as well as improve product production efficiency, overall product consistency, and quality.

Investment Focus & Key Milestones:

The expansion project focuses on upgrading IFUS’ production site in Napoleonville, LA by installing proprietary machinery to meet customer demands. This improvement advances IFUS’ ability to cost-effectively replicate IFUS’ Corporate Production Footprint both domestically and globally.

The new equipment allows for:

  • Increased production capacity and reduced lead times.
  • Improved product quality and consistency.
  • Lowered operational costs through energy efficiency, automation, and more.

Once more, we are “Back to work!”

mwalther@impactfusionintl.com

We can also be reached at 1-800-775-4130 seven days a week.

About Impact Fusion International Inc.
Impact Fusion International, Inc. is in the business of marketing products in the “Health and Wellness” sector of all international markets. It is the company’s mission to invent, develop and market these proprietary products worldwide for the health and well-being of humans and animals.

The information contained in this release includes some statement that are not purely historical and that are “forward-looking statements.” Such forward-looking statements include, but are not limited to, statements regarding our and their management’s expectations, hopes, beliefs, intentions or strategies regarding the future, including our financial condition, results of operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “would” and similar expressions, or the negatives of such terms, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this release are based on current expectations and beliefs concerning future developments and the potential effects on the parties and the corporate and administrative transactions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Impact Fusion International Inc.
204 Highway 1011
Napoleonville LA 70390
1-800-775-4130
Email: mwalther@impactfusionintl.com

https://www.impactfusionbrands.com/brands

Updates can be found at the official Impact Fusion Twitter account @impactfusionI

#madeUSA #newmachinery #Foodintelligence #NewMexico #healthiercattle #Screwworms #Intact #Digestion #Endurance #Germany #Colorado #legislation #bagasse #drought #SUAREC #Louisiana #Louisiana State Law HCR-42 2024
#greenhousegases #methanegas #cattle #dairy #Texasfloods #strawberries #citrus trees #blackberries #black currant #Texaswildfires $#Wagyu #India #Black Farmers National #Florida Statewide Organization (FSO) of Omega Psi Phi Fraternity, Inc. #Association #Supreme AG™ #SGP+™ #Oklahoma # Florida Oranges #Kansas #Arizona #KECO 96.5 FM radio #India #Australia #Brazil #Argentina #Canada #Vietnam #U.K. #Africa

The issuer is solely responsible for the content of this announcement.

New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions

By
Advertorial Desk
-

SEOUL, South Korea, Aug. 14, 2026 /PRNewswire/ — Enteric capsules are widely used to protect acid-sensitive compounds and to delay drug release until intestinal entry. However, evidence supporting their gastric integrity under physiologically relevant fed-state conditions remains limited, as most data rely on conventional static in vitro dissolution tests.

In this study, the authors from Bioneer A/S, the University of Copenhagen, and Lonza Capsugel evaluated the gastric integrity of their enteric capsules – Capsugel® Enprotect® capsules, using the Dynamic Gastrointestinal Model (DGM), which simulates the physical, hydrodynamic, and biochemical conditions of the human gastrointestinal tract under fasted and fed states. The DGM simulated key physiological factors such as gastric motility, pH changes, digestive secretions, and gastric emptying patterns.

Capsugel® Enprotect® capsules, offer a next-generation enteric delivery solution designed to protect acid-sensitive APIs and enable targeted release in the small intestine. These capsules have been developed using a first-of-its-kind manufacturing process. The bi-layered capsule manufacturing technology allows target delivery of APIs to the distal small intestine without the need for post-filling coating excipients, which accelerates the drug manufacturing and development processes. They avoid exposure to heat and solvents to protect against degradation for some APIs. 


To evaluate this performance, researchers filled the capsules with caffeine, a well-characterized model compound, and tested them under three conditions:

  • Fasted state
  • Light meal (~500 kcal)
  • High-fat FDA meal (~900 kcal)

Results showed caffeine‑filled Capsugel® Enprotect® capsules remained intact throughout gastric transit across all tested conditions, with release occurring only after intestinal entry. No caffeine was detected in stomach samples, indicating that the capsules did not prematurely release their contents. The capsules only disintegrated after entering the intestinal compartment, confirming their gastro-resistant properties. The capsules remained in the stomach for approximately 29 minutes in the fasted state, 147 minutes after the light meal, and 243 minutes following the high-fat meal. Despite this prolonged exposure, the capsules maintained their structural integrity.

Importantly, DGM‑based predictions of gastric residence time, capsule disintegration, and pharmacokinetic profiles closely aligned with previously published human MRI and salivary tracer data in the fasted state and after a light meal. One of the study’s most significant findings was that even under the challenging conditions of a high-fat meal, where gastric pH remained elevated for an extended period and stomach emptying was substantially delayed, the capsules still remained intact. The study also indicates that capsule floating behavior and the presence of an acidic “acid pocket” in the stomach may have helped preserve capsule integrity despite the less acidic environment.

Overall, these findings confirm the robust gastro‑resistant performance of Capsugel® Enprotect® capsules and highlight the value of biorelevant in vitro tools to predict oral dosage form behavior beyond standard dissolution testing.

Join Us at CPHI Korea 2026 and Discover the Future of Targeted Ingredient Delivery

As one of Asia’s premier pharmaceutical and nutraceutical industry events, CPHI Korea 2026 connects pharma and nutraceutical leaders across Asia to discover emerging technologies, exchange industry insights, and build partnerships driving innovation in health and nutrition. A key highlight at this year’s event will be Capsugel® Enprotect® capsules, our innovative enteric capsule technology designed to provide reliable gastric protection and targeted ingredient delivery without the need for additional enteric coating processes.

Visit us at Booth K15, COEX, Seoul, South Korea, 25-27 August 2026, and discover how Capsugel® Enprotect® capsules and our advanced delivery technologies can help bring your next innovation to market faster and more effectively.

For more information on Capsugel® Enprotect® capsules, please visit us at CPHI Korea.

ScitiX Introduces Production-Ready Inference Platform, Bringing Enterprise-Grade Control to Multi-Model AI Deployments

By
Advertorial Desk
-

SAN FRANCISCO, Aug. 17, 2026 /PRNewswire/ — ScitiX unveiled the full scope of its production inference platform, purpose-built for enterprises running AI at scale. As organizations move from experimentation to live workloads, the company is positioning inference not as a supporting function, but as the operational core of modern AI stacks.

The platform—running entirely on ScitiX-owned and operated NVIDIA B200, H200, and H100 infrastructure—delivers a unified execution layer that abstracts away the complexity of model orchestration, while giving customers granular control over performance, cost, and compliance. Current production metrics include over 1 trillion tokens processed daily, average time-to-first-token of approximately one second, a cache hit rate exceeding 90%, and 99.9% uptime.


What the Platform Does

ScitiX Model Inference is designed for enterprises running multiple models simultaneously—whether open-source, fine-tuned, or third-party. Rather than lock customers into a single model provider, the platform serves as a neutral, high-performance routing layer that standardizes access through familiar APIs.

Key capabilities include:

  • Intelligent model routing and fallback — Automatically directs queries to the optimal model based on latency, cost, or quality targets, with failover built in.
  • Session-aware context reuse — Maintains long-running conversational state and caches intermediate results, drastically reducing redundant compute.
  • Fault-tolerant execution — Handles retries, timeouts, and partial failures gracefully, so a single misbehaving call doesn’t break the entire workflow.
  • Private deployment environments — Dedicated tenancy options for workloads with strict data residency or security requirements.
  • Zero-retention policies — Ensures no customer prompts or outputs persist beyond the transaction, meeting the most stringent compliance standards.
  • Full-stack observability — Provides infrastructure-level telemetry, audit logs, and performance dashboards that surface exactly where latency or cost is coming from.


These capabilities are not theoretical. They are live today, supporting some of the most demanding inference workloads in production—including those from RadixArk, the commercial team behind SGLang, which runs its heaviest scenarios on ScitiX. “As inference gets more complex, the underlying infrastructure becomes the differentiator,” RadixArk noted. “ScitiX delivers the responsiveness and reliability we depend on.”

Designed for the Realities of Production AI

The platform addresses a specific pain point that has become increasingly apparent across enterprise deployments: model quality matters, but model operations matter just as much. Production failures rarely trace back to model weights. They stem from runtime variability, configuration drift, sandbox timeouts, and unpredictable infrastructure behavior.

ScitiX’s internal evaluation framework, SiEval, reflects this philosophy. Rather than treat evaluation as a leaderboard exercise, SiEval examines the entire execution chain—how results are produced, whether execution paths are reproducible, and whether outputs can support high-stakes decisions like release approval, rollback, or checkpoint promotion. In internal testing, SiEval demonstrated up to 10.5× acceleration on evaluation-heavy pipelines and 7.22× end-to-end speedups across large-scale leaderboard workflows, with the largest gains in pipelines involving LLM judges, sandboxed code execution, and long-context processing.

Why Enterprises Are Shifting to an Inference-First Model

The economics of AI have shifted. Token prices are falling, but total operational spend is not—because every user interaction can cascade into dozens of internal inference calls. As agentic workflows multiply, managing that complexity with per-model point solutions becomes unsustainable.

ScitiX’s bet is straightforward: the infrastructure layer that manages execution, governance, and observability will matter as much as the models themselves. The platform is built to give enterprises control over the variables that actually impact their bottom line—latency SLAs, per-request cost, data governance, and model agility.

“We are not building another model,” said ScitiX. “We are building the operational layer that makes multi-model production viable. Enterprises should not have to become GPU operators to deploy AI. They need flexibility, control, and a platform that handles the rest.”

Availability

ScitiX Model Inference is available now to enterprise customers. For more information on deployment options, pricing, and supported models, visit [https://www.scitix.ai/inference].

About ScitiX

ScitiX provides production-grade AI inference and operations infrastructure, built on company-owned NVIDIA B200, H200, and H100 clusters. The platform offers a unified execution layer that improves performance, governance, reliability, and cost efficiency across multi-model environments.

Forward-Looking Statements & Disclaimers

This release contains forward-looking statements regarding platform capabilities, market adoption, and infrastructure evolution. Actual results may differ materially. Performance metrics, customer statements, and internal test results—including token volume, latency, cache rates, uptime, and acceleration figures—are provided for illustrative purposes only and do not constitute service-level guarantees. Actual performance depends on workload characteristics, model architecture, deployment configuration, network conditions, and customer environment.

NVIDIA, B200, H200, and H100 are trademarks of NVIDIA Corporation. Other names and brands may be claimed as the property of their respective owners.

Vinfast partners with Gowa Motor Group to establish a joint venture and expand dealership network in Indonesia

By
Advertorial Desk
-

JAKARTA, INDONESIA – Media OutReach Newswire – 17 August 2026 – VinFast and Gowa Motor Group, an established Indonesian automotive group with experience across multiple automotive brands, today announced the signing of a strategic Memorandum of Understanding (MOU) to establish a joint venture that will develop VinFast’s electric vehicle dealership network in Indonesia. The partnership marks an important milestone in VinFast’s strategy to expand its presence in one of Southeast Asia’s most promising EV markets, bringing VinFast’s products, services, and EV ownership experience closer to consumers across the Indonesian archipelago.

Mr. Sadikin Aksa, Commissioner of Gowa Motor Group (left), and Mr. Antonio Zara, Chief Executive Officer of VinFast Southeast Asia (right), at the signing ceremony of the strategic Memorandum of Understanding (MOU) between VinFast and Gowa Motor Group.
Mr. Sadikin Aksa, Commissioner of Gowa Motor Group (left), and Mr. Antonio Zara, Chief Executive Officer of VinFast Southeast Asia (right), at the signing ceremony of the strategic Memorandum of Understanding (MOU) between VinFast and Gowa Motor Group.

Under the MOU, VinFast and Gowa Motor Group will establish a joint venture to develop VinFast’s dealership network across Indonesia, with a target of opening at least 30 showrooms and service centers.

The partnership reflects the two companies’ shared commitment to building a long-term strategic relationship in Indonesia’s growing electric vehicle market. By partnering with VinFast, Gowa Motor Group demonstrates its confidence in VinFast’s vision, capabilities, and the long-term potential of its electric mobility ecosystem.

The new network will serve as a key pillar of VinFast’s long-term growth strategy in Indonesia, offering VinFast’s electric vehicles alongside aftersales services, maintenance, and customer care that meet the company’s global standards. The partnership will contribute to VinFast’s broader plan to expand its dealership network in Indonesia. The company currently operates more than 40 showrooms nationwide and aims to add over 150 new showrooms in the coming years.

The agreement with Gowa Motor Group reinforces VinFast’s strategy of partnering with leading local companies to expand its distribution network, improve customer access to high-quality products and services, and support Indonesia’s transition toward greener transportation.

Gowa Motor Group is an established automotive group in Indonesia with extensive experience across multiple automotive brands and vehicle segments. Its operation spans automotive distribution, dealership operations, passenger vehicles, and commercial vehicles, supported by a broad network and strong understanding of the local market. With its automotive expertise, operational capabilities, and market knowledge, Gowa Motor Group is expected to become a strategic partner for VinFast in expanding its distribution network, enhancing the customer ownership experience, and accelerating the adoption of electric vehicles in Indonesia.

Representatives of VinFast and Gowa Motor Group at the MOU signing, marking an important step toward establishing a joint venture to expand 30 VinFast dealership showrooms across Indonesia.
Representatives of VinFast and Gowa Motor Group at the MOU signing, marking an important step toward establishing a joint venture to expand 30 VinFast dealership showrooms across Indonesia.

Mr. Antonio Zara, Chief Executive Officer of VinFast Southeast Asia, said: “Gowa Motor Group is an established automotive group in Indonesia with extensive experience across multiple automotive brands. We believe the combination of VinFast’s product development capabilities, advanced technologies, and comprehensive EV ecosystem with Gowa Motor Group’s local market expertise, automotive network, and operational experience will provide a strong foundation for expanding VinFast’s presence in Indonesia. More importantly, this partnership will enable us to deliver an increasingly convenient, comprehensive, and high-quality EV ownership experience for Indonesian customers.“

Mr. Sadikin Aksa, Commissioner of Gowa Motor, said: “We see tremendous potential in Indonesia’s electric vehicle market and strongly believe in VinFast’s long-term vision. Our partnership not only creates new business opportunities for both companies but also reflects our shared commitment to accelerating Indonesia’s green transition. Leveraging our experience across multiple automotive brands and our established network in Indonesia, Gowa Motor Group looks forward to working alongside VinFast to bring sustainable mobility solutions and high-quality services closer to consumers across the country.“

Indonesia is one of the key pillars of VinFast’s global growth strategy. Since entering the market, VinFast has rapidly expanded its product portfolio, commenced operations at its manufacturing facility in Subang, and built a comprehensive EV ecosystem through a growing network of strategic partners, including charging infrastructure developer V-Green, all-electric ride-hailing service GSM, financial institutions, banking partners, authorized service workshop partners, and dealerships nationwide. By combining manufacturing capabilities, a comprehensive EV ecosystem, and an expanding partner network, VinFast is steadily advancing toward its goal of becoming one of the leading electric vehicle brands in Indonesia and across Southeast Asia.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

About VinFast

VinFast (NASDAQ: VFS), a subsidiary of Vingroup JSC, one of Vietnam’s largest conglomerates, is a pure-play electric vehicle manufacturer with the mission of making EVs accessible to everyone. VinFast’s product lineup today includes a wide range of electric SUVs, e-scooters, e-bikes, and electric buses.

In Indonesia, VinFast is expanding its electric mobility ecosystem through a growing dealership and after-sales network, local partnerships, and its manufacturing facility in Subang, West Java, reinforcing its long-term commitment to the market.

Learn more at:

About Gowa Motor Group

Gowa Motor Group is an established automotive group in Indonesia with extensive experience in the automotive sector. The Group represents and operates across multiple automotive brands and vehicle segments, including passenger and commercial vehicles, supported by dealership, distribution, and customer service capabilities. With a broad network across Indonesia and a strong understanding of the local automotive market, Gowa Motor Group continues to build long-term partnerships and expand access to quality mobility products and services.

Yanolja Cloud Solution Introduces AI Concierge for Hotel Operations

By
Advertorial Desk
-

Following validation across more than 1,000 hotels in India, AI concierge solution expands globally with planned rollouts across Thailand, the United States, Malaysia and Africa

SEOUL, South Korea, Aug. 17, 2026 /PRNewswire/ — Yanolja, a global travel technology company, today announced the global rollout of an AI concierge solution developed by its hospitality technology subsidiary, Yanolja Cloud Solution (YCS), following a preview program across more than 1,000 hotels in India. The solution will expand to Thailand, the United States, Malaysia and Africa.


“As AI reshapes the hospitality industry, hotels are looking beyond automation to intelligent systems that can execute operational tasks and elevate the guest experience,” said Aeijaz Sodawala, CEO of Yanolja Cloud Solution. “Our AI concierge brings together specialized AI agents, real-time operational data and deep hospitality expertise to simplify daily operations, empower hotel staff and deliver more seamless guest experiences.”

Hotels are increasingly adopting AI to automate repetitive operational tasks while enabling staff to focus on higher-value guest interactions. According to YCS, a typical 25-room hotel spends up to eight hours each day handling routine guest communications, including reservation inquiries, check-in and check-out requests, and room service coordination.

Purpose-built for hotel operations, the AI concierge is powered by a multi-agent architecture in which eight specialized AI agents collaborate across core functions, including guest communications, reservations, check-in and check-out, housekeeping, room service, payments and upselling. Through direct integration with the YCS Property Management System (PMS), the solution accesses real-time reservation and room availability data to execute operational tasks rather than simply respond to guest inquiries.

Guests can interact with the AI concierge through WhatsApp or a web-based Guest Portal to confirm reservations, complete digital check-in, request hotel services and make payments. When human assistance is needed, conversations can be seamlessly transferred to hotel staff in real time.

About Yanolja Co., Ltd.

Yanolja is a global technology company transforming the future of travel. We provide a Travel Enablement Platform (powered by data) for travelers and travel enterprises across every stage of the journey — pre-trip, in-trip, and post-trip — delivering efficiency for travel enterprises and seamless, personalized experiences for travelers.

Yanolja is revolutionizing the global travel ecosystem — making travel smarter, easier, and more connected for everyone, everywhere.

About Yanolja Cloud Solution

Yanolja Cloud Solution is a global hospitality technology company, providing an AI-powered hospitality platform that helps hotels and enterprise hospitality groups simplify operations, maximize revenue, and elevate every stage of the guest journey.

Trusted by more than 33,000 hospitality businesses across 170+ countries, our intelligent platform brings together hotel operations, distribution, direct bookings, payments, and guest engagement in one connected experience, empowering hoteliers to operate smarter and grow with confidence.

With more than 650 technology integrations and support for over 574,000 rooms daily, Yanolja Cloud Solution is helping shape the future of hospitality through connected technology and continuous innovation.

JUNEiNTER Unveils the LCP Game Revenue Estimation Model

By
Advertorial Desk
-

Special Event for F2P Game Developers Launches Alongside the Announcement


SINGAPORE- Media OutReach Newswire – 17 August 2026 – With the global game market grown to an approximate value of US$200 billion annually, JUNEiNTER unveils a model designed to estimate the future revenue of individual games.

JUNEiNTER announced the release of the “LCP Model,” which estimates future revenue based on operating data from live service games and a public event of a free-trial marking its launch.

Whereas games generate recurring monthly cash flows and function as digital assets, the industry has lacked established standards to calculate the future revenue of individual titles — making their revenue streams difficult to be utilized as measurable financial assets.

The LCP Model was developed from the fundamental question: “How much revenue will our game generate?” The S66 Engine, which applies the LCP Model, analyzes actual service data accumulated from launch to calculate potential future revenue. Accordingly, it has been simulated about 90,000 times, confirming its consistency and reproducibility.

To mark the unveiling of the LCP Model, JUNEiNTER is holding a public event for developers to get revenue estimations for their own games. Eligible participants are games that use the F2P model monetized through in-app purchases (IAP) or combining in-app purchases with in-app advertising. Steam and console games are excluded.

Participating developers will also be offered additional special benefits for future usage. Eligibility requirements and details of the benefits are available on JUNEiNTER’s official website (https://gv.juneinter.com).

A JUNEiNTER spokesperson said, “Revenue estimates generated by the S66 Engine are not intended to be investment solicitation, fundraising, or a guarantee of returns. The results are estimates based on the data submitted by developers and the model’s criteria, and may differ from actual revenue.”

Media Contact
Teresa Lee / Business Operations Team / jl908@juneinter.com / +82-10-2144-4979 /
Hashtag: #LCPmodel #S66 #JUNEinTER #gamerevenueestimation #mobilegaming #gamedevelopers #B2B #F2P #gamevaluation #live-service #gaming

The issuer is solely responsible for the content of this announcement.

JUNEiNTER Co., Ltd

Founded in 2002, JUNEiNTER Co., Ltd. is a South Korean game company that has developed, serviced, and published online and mobile games, best known for publishing GetAmped (PC) and My Oasis (mobile). The company has expanded its lineup through in-house development, co-development, and investment over the years.

Soterion’s SAP License Manager Passes 100 FUE Assessments as Customers Confront the Cost of SAP’s STAR Licensing

By
Advertorial Desk
-

One year after launch, the module has completed 100 Full User Equivalent assessments, sizing SAP licensing on what users actually do rather than on the access they are assigned

SYDNEY, Aug. 17, 2026 /PRNewswire/ — Soterion today announced that its SAP License Manager has completed its 100th Full User Equivalent (FUE) licensing assessment, just one year after the module was launched. The milestone reflects the growing demand for specialist licensing expertise as organisations transition from SAP ECC to SAP Cloud ERP Private.

The demand is being driven by a fundamental change in how SAP measures user licensing. Under the STAR measurement framework used by SAP Cloud ERP Private, FUE consumption is determined by the SAP authorisations assigned to users, irrespective of whether those authorisations are ever used. Because most legacy SAP role designs were created without FUE optimisation in mind, many organisations are consuming significantly more FUEs than their users’ actual activities require.

With user licenses typically representing 30 to 60 percent of an organisation’s total SAP software investment, and FUE consumption measured monthly throughout the subscription period, an inflated starting point or unmanaged role changes can result in unnecessary subscription costs and future true-up exposure.

Soterion’s SAP License Manager analyses actual SAP authorisation usage rather than relying solely on assigned access. The solution provides organisations with three key metrics: the FUE consumption based on their current role design, the reduction achievable through role remediation, and the best-case FUE requirement based on how users genuinely interact with SAP.

Across its first 100 assessments, Soterion found that legacy SAP role designs typically overstated organisations’ FUE requirements by approximately four times. 

By providing visibility into actual SAP authorisation usage, Soterion has helped organisations understand their true FUE requirements before entering commercial negotiations with SAP. For organisations already operating on SAP Cloud ERP Private, the solution has enabled targeted FUE remediation programmes to align FUE consumption with contracted entitlements, while providing ongoing visibility to proactively manage license consumption throughout the subscription term.

“SAP’s STAR rule set is actually very fair. I would even argue that it is relatively lenient,” said Dudley Cartwright, CEO and co-founder of Soterion. “The real challenge is that most organisations have not had the time, or the tools, to redesign their SAP roles with FUE optimisation in mind. As a result, many are consuming more FUEs than necessary. Our role is to provide the visibility organisations need to reduce unnecessary consumption, align with their contracted entitlements, and establish sustainable FUE governance.”

Cartwright added, “SAP role design is no longer just a security consideration. It has become a financial control. Every role change now has the potential to affect both access risk and software licensing costs.”

“Completing 100 assessments in our first year demonstrates how significant this challenge has become. As organisations work towards SAP ECC end of maintenance deadlines and migrate to SAP Cloud ERP Private, many are recognising that effective FUE management has become an essential part of a successful migration strategy.”

Soterion offers a complimentary SAP FUE assessment to help organisations understand their current FUE consumption, identify optimisation opportunities, and establish an informed baseline before negotiating or managing SAP Cloud ERP Private subscriptions.

About Soterion

Soterion is an international provider of business-centric Governance, Risk and Compliance (GRC) and SAP FUE licensing software for companies running SAP. Founded in 2011, Soterion translates technical SAP access and authorisation data into business-friendly language, helping organisations manage access risk and optimise SAP licensing.

Media contact
Soterion 
info@soterion.com 
https://soterion.com

1...274275276...6,697Page 275 of 6,697